# Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis

> **NCT01380314** · PHASE2 · COMPLETED · sponsor: **Foundation Fader** · enrollment: 60 (estimated)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **DRUG:** Miltefosine + Imiquimod
- **DRUG:** Miltefosine 150 mg x day + Placebo

## Key facts

- **NCT ID:** NCT01380314
- **Lead sponsor:** Foundation Fader
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380314, "Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01380314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*